Chemistry 250 Course: Advances in Pharmaceutical Research
Noyes 153 (J. Holmes Sturdivant Lecture Hall)
Process Chemistry Development of Ledipasvir − NS5A Inhibitor in Harvoni® for Hepatitis C Treatment
Robert W. Scott,
Dr., Ph.D., Senior Director,
Process Development,
Gilead Sciences, Inc.,
This presentation will outline the development of the synthetic chemistry route to Ledipasvir, which is combined with Sofosbuvir in the Hepatitis C treatment Harvoni®. Ledipasvir is a highly-potent NS5A inhibitor with an unsymmetric benzimidazole-difluorofluoroene-imidazole core coupled to distal bicyclic pyrrolidine-based ring systems. Key developments of the process route, from the initial Discovery chemistry synthesis through commercial scale, will be discussed.
For more information, please contact Lynne Martinez by phone at 626-395-4004 or by email at [email protected].